T HE ANDROGEN RECEPTOR (AR), a transcription factor, belongs to the nuclear receptor superfamily (1, 2) . Once bound to androgen, AR translocates into the nucleus, leading to activation of its target genes (3) . AR consists of the amino-terminal region that is involved in transcriptional activation, the DNA-binding domain (DBD), the hinge region that contains the nuclear localization signal, and the ligand-binding domain (LBD) that is involved in androgen binding and receptor dimerization (3) . It is generally accepted that AR plays an important role in the development of the reproductive organs and in progression of prostate cancer (3) (4) (5) . Maximal or proper androgen action may require the interaction of AR with several coregulators (6) , such as ARA70 (7, 8) , ARA55 (9, 10), ARA54 (11, 12) , and steroid receptor coactivator-1 (13) .
The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10), located at chromosome 10q23, is one of the most frequently mutated genes linked to a variety of human cancers (14) (15) (16) (17) (18) (19) (20) . Germline mutations in PTEN cause the autosomal dominant inherited cancer syndromes such as Cowden's disease, which is associated with an elevated risk for malignant cancers (21) . Loss of PTEN expression is frequently found in prostate cancer cell lines and tumor specimens (22) . Mice with a heterozygous mutant PTEN develop prostate epithelial hyperplasia and dysplasia (23) . Mice with inactivation of one allele of PTEN in combination with loss of the cyclin-dependent kinase (CDK)n1b (encoding p27 Kip1 ) gene have an acceleration of spontaneous neoplastic transformation and develop prostate carcinoma (24) . Interestingly, mice deficient in CDKn1b do not develop prostate cancer (25) (26) (27) , suggesting that PTEN and p27
Kip1 cooperate in prostate cancer suppression in the mouse. These results indicate that loss of PTEN function may be a key event in prostate cancer progression.
Recent studies demonstrated that PTEN regulates not only cell growth and apoptosis, but also controls cell adhesion and migration (28) (29) (30) . Whereas the PTEN sequence suggests that it may be a dual specificity phosphatase that includes lipid phosphatase and protein phosphatase activity, its protein substrates remain largely unknown. Recently, several groups have reported that the phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway is negatively regulated by PTEN through its phospholipid 3-phosphatase activity (16, 17, (31) (32) (33) . Whereas the PI3K/Akt-dependent pathway is the most popular model for PTEN action, other signaling pathways were also suggested (34) . For instance, dPTEN regulates cell growth and proliferation in Drosophila through the PI3K/Akt-dependent and -independent pathway (34) . Furthermore, using mouse embryonic fibroblasts (MEFs) from PTEN-null mice, Wu and coworkers (35) . showed that PTEN can physically interact with p53 and regulate protein stability and transcriptional activity without its phosphatase activity, indicating that PTEN regulates p53 function independent of the PI3K/ Akt pathway. As a consequence, loss of one allele of PTEN dramatically accelerates tumor formation of the p53 heterozygous mouse.
As androgen/AR plays important roles in prostate cancer progression, understanding the factors involved in the regulation of androgen/AR action may provide molecular targets for prostate cancer treatment. Here we demonstrate that PTEN regulates AR activity in low-passage number LNCaP cells via a PI3K/Akt-independent pathway and interacts directly with AR to suppress androgen-induced AR nuclear translocation. The interaction between AR and PTEN may expose the active site of the AR for the recognition of caspase-3, leading to AR degradation. In contrast, PTEN regulates AR activity in high passage number LNCaP cells via a PI3K/Akt-dependent pathway.
RESULTS

PTEN Suppresses AR Transactivation Involving the Pathways Other Than PI3K/Akt
The PTEN tumor suppressor induces cell apoptosis in a variety of cell types including prostate cancer cells. However, the molecular mechanism underlying PTENinduced apoptosis in prostate cancer cells remains unclear. We were interested in testing the potential linkage between PTEN and androgen/AR signaling. To test this hypothesis, we determined the effect of the PTEN on AR transactivation using mouse mammary tumor virus-luciferase (MMTV-luc) as an AR reporter. PTEN suppressed AR transactivation in a dosedependent manner in androgen-dependent prostate LNCaP cells and in androgen-independent prostate cancer PC-3 cells and DU145 cells (Fig. 1A) . Interestingly, PTEN C124S, a PTEN mutant without phosphatase activity, still can suppress AR activity in DU145, PC-3, and LNCaP cells, but to a lesser extent (Fig. 1A) . To rule out the possibility that the suppression of AR by PTEN might come from the suppressive effect of PTEN on general transcriptional machinery, we used pGL3-control vector (Promega Corp., Madison, WI) and pG5-Lucifase (a GAL4 reporter) as controls to demonstrate that PTEN has little or enhanced effect on these control luciferase vectors after being normalized with pRL-SV40 internal control used in all samples (Fig. 1B) . Northern blot analysis further confirmed that PTEN could suppress androgen-induced expression of prostate-specific antigen, an endogenous AR target gene, in prostate cancer LNCaP cells (Fig. 1C) .
It is generally believed that PTEN exerts its role in tumor suppression by negatively regulating the PI3K/ Akt pathway. We next determined whether PTEN affects AR activity via the regulation of the PI3K/Akt pathway in different passage numbers of LNCaP cells. The protein expression levels of AR and Akt are comparable between the low and high passages of LNCaP cells, but the basal Akt activity in high passage number LNCaP was much higher than in low passage number LNCaP cells (Fig. 1D) . Interestingly, in a low passage number of LNCaP cells (passage 25), PTEN suppresses AR activity via a PI3K/Akt-independent pathway, as addition of the constitutively active form of Akt (cAkt) does not reverse the suppressive effect of PTEN on AR activity (Fig. 1E, left panel, lane 4) . Interestingly, cAkt, like PTEN, also suppressed AR activity in low passage number LNCaP cells (Fig. 1E , left panel, lane 5). PI3K/Akt inhibitor, LY294002, did not significantly enhance AR activity (Fig. 1E , left panel, lane 6) perhaps due to a low basal activity of Akt in such cells (Fig. 1D) . However, restoration of Akt activity completely reversed the PTEN suppression of AR activity in high passage number LNCaP cells (Fig. 1E , right panel, lane 3), suggesting that PTEN can also regulate AR signaling via a PI3K/Akt-dependent pathway in LNCaP cells with different passage numbers. Unlike its suppression of AR activity in the lower passage number LNCaP cells, cAkt enhanced AR activity in the high passage number LNCaP cells (Fig. 1E . right panel, lane 5). Taken together, these contrasting results suggest that PTEN can regulate AR activity via the PI3K/Aktdependent and -independent pathways in prostate cancer LNCaP cells at different growth stages.
PTEN Interacts with AR in Vitro and in Vivo
Because PTEN regulates AR activity via a PI3K/Aktindependent pathway in the early-passage LNCaP cells, we hypothesized that PTEN might function via direct interaction with AR. Indeed, our glutathione-Stransferase (GST) pull-down assay results indicated that PTEN could interact with AR in the presence or absence of androgen ( Fig. 2A) . Among several nuclear receptors we tested, we found that PTEN binds preferentially to AR and estrogen receptor (ER), as compared with glucocorticoid receptor (data not shown), progesterone receptor (data not shown), or the retinoid X receptor ( Fig. 2A) .
To map the AR interaction domains on PTEN, the plasmids encoding a set of PTEN fragments fused with GST were constructed for the GST pull-down assays. The AR was able to interact with GST-PTEN-no. 2 [amino acids (aa) 107-252], where the phosphatase domain is located, but not with GST-PTEN-no. 1 (aa 1-107) or GST-PTEN-no. 3 (aa 253-403) (Fig. 2, B and C). Further peptide mapping revealed that PTEN-PTP (aa 110-163) containing the phosphatase domain is sufficient for interacting with AR (Fig. 2C) .
Studies of the PTEN-interacting domain on AR indicated that the AR-DBD (aa 486-651) and AR-DBD plus LBD (AR-DBD-LBD) (aa 552-918), but not the AR amino-terminal region (AR-N) (aa 34-560) or AR-LBD (aa 666-918), were able to interact with PTEN (Fig. 2,  D and E). The GST pull-down assay results therefore suggest that AR can interact with PTEN (aa 110-163) via its DBD (aa 552-651).
To further confirm the physiological interaction between AR and PTEN by coimmunoprecipitation, we established PTEN-stable LNCaP cells, using the doxycycline (Dox)-inducible system. Dox treatment induced expression of PTEN or PTEN C124S in several clones (PTEN-C1, PTEN-C2, PTEN C124S-C4, and PTEN C124S-C8, Fig. 3A ). AR could be coimmunoprecipitated with PTEN, when we used cell lysates from PTEN-C1 cells (Fig. 3B) . To rule out the possibility that PTEN antibody may cross-react with AR, we dem- onstrated that PTEN antibody did not pull down AR, using parental LNCaP cells, which express AR but not PTEN (data not shown). To further prove that endogenous PTEN can interact with the endogenous AR in the prostate cancer cell line, we applied the CWR22R cell line (36, 37) , which endogenously expresses both AR and PTEN (Fig. 3C ), for coimmunoprecipitation with PTEN antibody. The results showed that AR could be detected in the PTEN-immunoprecipitated complex (Fig. 3C) . To further determine whether the DBD plus the hinge region of AR (aa 486-651, AR-D) can interact with PTEN, we transfected AR-D into CWR22R cells for coimmunoprecipitation with PTEN antibody. We found AR-D could be found in PTENimmunoprecipitated complex (Fig. 3D) . Interestingly, AR-D could also prevent endogenous PTEN from binding to AR in CWR22R cells (Fig. 3D) . These results suggest that AR can physiologically interact with PTEN through the AR-D region in prostate cancer cells.
PTEN Colocalizes with AR and Inhibits AR Nuclear Translocation
The interaction between PTEN and AR was also analyzed by the subcellular colocalization study, using fluorescence immunostaining. As shown in Fig. 4A , the fluorescent FITC-stained PTEN was located mainly in the cytosol, but small amounts of PTEN were also found in the nucleus. Similar to the FITC-stained PTEN, Texas Red-stained AR was also located mainly in the cytosol in the absence of androgen, but androgen treatment caused AR nuclear translocation (Fig.  4A ). Figure 4B further demonstrates that PTEN could colocalize with AR in the presence or absence of androgen. Interestingly, we found that PTEN significantly blocked AR nuclear translocation in response to androgen and increased the AR retention (from 4% to 38%) in the cytosol. In contrast, PTEN C124S showed only a slight inhibition of AR nuclear translocation (Fig.  4C) . Similar results were also obtained in LNCaP cells with stable transfection of PTEN (passage 40). As shown in Fig. 4D , Dox-induced PTEN expression in the PTEN-stable PTEN-C2 cells could inhibit the AR nuclear translocation. In contrast, Dox showed little effect on the AR nuclear translocation in the parental pBIG2i cells. These results suggest that PTEN may be able to bind to AR and prevent the translocation of cytosolic AR into the nucleus, which may then result in suppression of AR transactivation.
Fig. 3. PTEN Interacts with AR in Vivo
A, The establishment of stable PTEN and PTEN C124S clones in LNCaP cells using Dox-inducible system. The cells were treated with 4 g/ml Dox for 24 h and harvested for Western blot analysis using PTEN antibody. PTEN and PTEN C124S expression can be induced with Dox treatment in Clone C1 and C2, and C4 and C8, respectively. B, AR exists in the PTEN immunocomplex in LNCaP cells overexpressing PTEN. The stable PTEN clone (PTEN-C1) was treated with or without 4 g/ml Dox in 10% CDS media for 24 h and treated with ethanol or 10 nM DHT for another 24 h. The cells were harvested for immunoprecipitation (IP) assay with normal mouse PTEN antibody, followed by Western blotting with AR antibody. The total cell lysates were subjected to Western blotting with PTEN and AR antibodies. C, Endogenous association between PTEN and AR in CWR22R cells. The IP and Western blot methods used are the same as described in panel B except that the cell lysates were from the CWR22R cells. D, The PTEN-AR interaction is inhibited by AR-D in CWR22R cells. The cells cultured in RPMI medium with 10% FCS were transfected with vector or FLAG-tagged AR-D for 48 h. Cells were then harvested for immunoprecipitation (IP) assay with normal mouse IgG or PTEN antibody, followed by Western blotting with AR or FLAG antibodies. The total cell lysates were subjected to Western blotting with FLAG, PTEN, and AR antibodies.
PTEN Decreases AR Protein Levels via Promotion of AR Degradation
To determine whether PTEN suppression of AR transactivation involves the modulation of AR protein stability, we assessed the transient transfection and Western blot analyses. We found that PTEN could reduce AR protein levels in COS-1 cells (Fig. 5A ). To rule out the possibility that PTEN may influence the promoter activity of the AR expression plasmid, we tested the expression of endogenous AR in PTENstable LNCaP cells. As shown in Fig. 5B , Dox-induced expression of PTEN in LNCaP PTEN-C1 and PTEN-C2 reduced endogenous AR protein levels. In contrast, Dox-induced PTEN C124S expression in PTEN-C124S-C4 and PTEN-C124S-C8 failed to reduce endogenous AR protein levels. Together, our data clearly demonstrate that PTEN could interact with AR and reduce AR protein levels in COS-1 and LNCaP cells. To determine whether the reduced AR protein levels were due to reduced mRNA expression, a portion of each LNCaP cell lysate was subjected to Northern blot analysis. Whereas AR protein levels were reduced by Dox-induced PTEN, the AR mRNA 
. PTEN Colocalizes with AR in Vivo and Prevents AR Nuclear Translocation
A, The COS-1 cells were transfected with AR or PTEN in 10% CDS media for 16 h and treated with ethanol or 10 nM DHT for another 16 h. The cells were fixed and stained with AR and PTEN antibodies, followed by examination with confocal microscopy. B, The COS-1 cells were transfected with AR and PTEN and treated with ethanol or 10 nM DHT for another 16 h. The cells were fixed and stained with AR and PTEN antibodies, followed by examination with confocal microscopy. The green and red colors represent PTEN and AR staining, respectively, and the yellow color represents PTEN and AR colocalization. C, COS-1 cells were transfected with pSG5-AR along with pCDNA3, pCDNA3 PTEN, or PTEN C124S and treated with ethanol or DHT in 10% CDS media for 16 h. The arrows indicate PTEN-positive cells, which show AR located in the cytosol. At least 150 cells were scored for each sample, and data are means Ϯ SD from three independent experiments. D, The pBIG2i or PTEN-C2 LNCaP cells were treated with 4 g/ml Dox for 24 h, followed by 10 nM DHT for another 16 h. The cells were fixed for immunostaining. E, The COS-1 cells were transfected with AR in combination with plasmids, as indicated on the right for 16 h, followed by 10 nM DHT treatment for another 16 h. The cells were fixed for immunostaining. levels normalized by ␤-actin remained relatively unchanged (data not shown), suggesting that PTEN may reduce the AR protein levels through posttranscriptional modification.
We then studied AR protein stability by pulse chase labeling. As shown in Fig. 5C , PTEN clearly reduced the half-life of newly synthesized [
35 S]AR 4-to 5-fold and accelerated AR degradation. Interestingly, when we replaced PTEN with either the dominant negative form of Akt (dAkt) or PI3K inhibitor LY294002, the results (data not shown) indicated that dAkt and LY294002 did not promote AR degradation, ruling out the possibility that PTEN promotes AR degradation via regulation of the PI3K/Akt pathway. In agreement with the phenomenon that PTEN promotes AR degradation via the non-PI3K/Akt pathway, the stability of the endogenous AR in the early-passage LNCaP cells (passage 38), where the PTEN effect on AR is suggested to be independent of the PI3K/Akt pathway (Fig. 1E) , was clearly reduced in the presence of PTEN (Fig. 5D ). These data strongly suggest that other pathways, such as direct PTEN-AR protein-protein interaction, may play major roles for the PTEN-promoted AR degradation. In contrast, in high passage number LNCaP cells (passage 65) where the PI3K/Akt pathway becomes dominant (Fig. 1, D and E) , PTEN-induced AR degradation was suppressed by cAkt (Fig. 5E ), suggesting that the suppressive effect of PTEN on AR It has been suggested that PTEN regulates the stability of p27 kip1 via a ubiquitin-proteasome pathway (38) . Whereas MG132, a proteasome inhibitor, blocked estrogen-mediated ER degradation (see supplemental Fig. 1A , right panel, published as supplemental data on The Endocrine Society's Journals Online web site at http://mend.endojournals.org), it did not prevent PTEN-mediated AR degradation (see supplemental Fig. 1A, left panel) , suggesting that PTEN promotes AR protein degradation via a proteasome-independent pathway. Interestingly, we found that the caspase-3 inhibitor DEVD-CHO, can block PTEN-mediated AR degradation (see supplemental Fig. 1B) . We demonstrated that caspase-3 could cleave AR into three evident fragments, and DEVD-CHO completely blocked caspase-3-mediated AR degradation (see supplemental Fig. 1B) , consistent with the previous reports (39) .
Interaction between PTEN and AR Contributes to PTEN-Induced Suppression of AR Functions and Apoptosis
To further prove that PTEN suppression of AR function may go through direct PTEN-AR interaction, we used AR-D, which can interact with PTEN and disrupt the interaction between AR and PTEN in the CWR22R cells (Fig. 3D) , for functional studies. Our results further showed that AR-D could dramatically reduce PTEN-mediated inhibition of AR nuclear translocation (Fig. 4E) , PTEN-mediated promotion of AR degradation (Fig. 6A) , and PTEN-mediated suppression of AR transactivation (Fig. 6B) , suggesting that PTEN and AR interaction plays important roles for the PTEN effects on AR nuclear translocation, AR protein degradation, and AR transactivation. To extend our studies of PTEN on the suppression of AR function, we applied AR-D to another prostate cancer cell line, CWR22R, which expresses functional AR and PTEN (36, 37) . As shown in Fig. 6C , PTEN dramatically suppressed AR transactivation. Remarkably, AR-D could significantly reduce PTEN suppressive effect on AR transactivation (Fig.  6C) . Furthermore, the PTEN mutant devoid of AR binding region (⌬ aa121-200, PTEN-dPTP) failed to suppress AR expression (Fig. 6D) and transactivation (Fig.  6E) . These results therefore are in agreement with the results from LNCaP cells (Fig. 6B ) and suggest that PTEN may be able to modulate AR functions by direct interaction with AR in the various stages of prostate cancers.
The PTEN tumor suppressor induces cell apoptosis in a variety of cell types including the LNCaP cells. To determine whether suppression of AR activity by PTEN contributes to PTEN-induced apoptosis, we used the TUNEL (terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate nick end-labeling) assay to study the effect of AR-D, which could partially relieve suppression of AR transactivation by PTEN (Fig. 6 , B and C), on PTEN-induced apoptosis in LNCaP cells (passage 35). As expected, PTEN could induce apoptosis markedly, whereas PTEN C124S showed only a marginal effect, and AR-D markedly reduced PTEN-induced apoptosis (Fig. 6F) . The suppressive effect of AR-D on PTEN functions was not due to the interference of PTEN phosphatase activity, because AR-D showed little influence on the PTEN-mediated inhibition of Akt activity (data not shown). Together, these data clearly suggest that interaction between PTEN and AR contributes to PTEN-induced suppression of AR functions and apoptosis. Our results (Fig. 6F ) also confirmed an earlier report (39a) that PTEN-induced cell death could be reversed by adding cAkt, suggesting that the PTEN3 PI3K3 Akt pathway also plays a role in the mediation of PTENinduced cell death.
To rule out the possibility that AR-D may have nonspecific effects, we used glioblastoma U87MG cells to test the effects of AR-D on the PTEN-induced apoptosis in AR-negative cells. Both Western blot assay and AR transactivation assay indicated that AR was undetectable in U87MG cells (data not shown). Whereas PTEN induced apoptosis in U87MG cells, the addition of AR-D showed only marginal effects on the PTENinduced apoptosis, and cAkt suppressed PTENinduced apoptosis (data not shown). These results suggest that the effect of AR-D on PTEN-induced apoptosis is specific and requires the intact AR signaling. Together, results from Fig. 6 clearly indicate that PTEN may have two distinct pathways (PTEN3PI3K/Akt and PTEN3AR) to induce apoptosis, and the interaction of PTEN with AR may play important roles in one of these two pathways in the LNCaP prostate cancer cells.
Inhibition of Endogenous PTEN Expression Increases AR Protein Levels and Transcriptional Activity
We have demonstrated that overexpression of PTEN promotes AR degradation and suppresses AR activity. To avoid the above observations resulting from overexpression, we used small interfering RNA (siRNA) to block endogenous PTEN and examined whether the AR protein levels and transcriptional activity would be affected by down-regulating PTEN. As shown in Fig. 7A , transient transfection of PTEN siRNA into human embryonic kidney 293T cells reduced endogenous PTEN protein levels up to 50-60%, which correlated with the transfection efficiency (ϳ50%) in our experiment conditions. As expected, reduction of PTEN expression enhanced AR protein expression in the presence and absence of androgen (Fig. 7A) . PTEN siRNA enhanced AR transactional activity in a dose-dependent manner in the presence of androgen in 293T cells (Fig. 7B) . Furthermore, we observed that the levels of AR protein expression in PTEN-null MEFs were much higher than that in WT MEFs (Fig. 7C) , suggesting that AR may be more stable in the absence of PTEN. Reintroduction of PTEN in PTEN-null MEFs drastically reduced AR protein levels, as compared with that in WT MEFs (Fig. 7C) . We also found that AR transcriptional activity in PTEN-null MEFs was much higher than in WT MEFs, and reconstitution of PTEN in PTEN-null MEFs significantly suppressed AR activity (Fig. 7D) . cAKt did not reverse the PTEN-mediated repression of AR activity (Fig. 7D) , suggesting that PTEN suppresses AR activity via the PI3K/Akt-independent pathway in MEFs. These results suggest that endogenous PTEN is a negative regulator for controlling AR protein stability and transcriptional activity.
DISCUSSION
The PTEN tumor suppressor induces cell apoptosis in a variety of cell types including the prostate cancer cells. However, the molecular mechanism underlying PTEN-induced apoptosis in prostate cancers remains largely unknown. In the present study we have identified AR as a novel target of PTEN in vitro and in vivo. PTEN inhibited AR nuclear translocation, promoted AR protein degradation, and inhibited AR transactivation via direct PTEN-AR interaction. We also demonstrated A, The LNCaP cells were transfected with indicated plasmids in 10% CDS media for 16 h, followed by treatment with 10 nM DHT for 24 h. Cells were then harvested, and the cell extracts were subjected to Western blotting with anti-AR or anti-Akt antibody. B, The LNCaP cells were transfected with indicated plasmids in 10% CDS media for 16 h, followed by treatment with 10 nM DHT for another 16 h. Cells were harvested and assayed for MMTV-luciferase activity. C, The CWR22R cells were transfected with plasmids, as indicated, using (ARE)4-luc as a reporter for 16 h, followed by ethanol or 10 nM DHT treatment for another 16 h. Cells were harvested for luciferase assay. D, The 293T cells cultured in DMEM containing 10% FCS were transfected with pCDNA3-AR, pCDNA3-FLAG-PTEN, pCDNA3-FLAG-PTEN-dPTP, and/or pEGFP-C1 (BD Biosciences, Franklin Lakes, NJ), as indicated, for 24 h, and harvested. The cell extracts were subjected to SDS-PAGE. Western blot analysis was performed, and AR and PTENs were detected by AR and FLAG antibodies, respectively. Enhanced green fluorescent protein expression was used for transfection and loading control. E, The CWR22R cells were transfected with plasmids, as indicated, using (ARE)4-luc as a reporter for 16 h, followed by ethanol or 10 nM DHT treatment for another 16 h. Cells were harvested for luciferase assay. F, The LNCaP cells were transfected with plasmids, as indicated, for 16 h, and the medium was changed to 0.1% CDS media for 2 d. The cell apoptosis was determined by TUNEL assay. PTEN, but not PTEN-no. 1 (aa 1ϳ107) or mutant PTEN-C124S, induced LNCaP cell apoptosis. Increased AR expression by transfection of AR, interrupting PTEN-AR interaction by AR-D, and overexpressing cAkt could rescue LNCaP cell apoptosis caused by PTEN. Data for luciferase activity and apoptosis are means Ϯ SD from three independent experiments. *, P Ͻ 0.05; **, P Ͻ 0.001 vs. control (indicated as F), Student's two-tailed t test.
that PTEN-induced suppression of AR transactivation and apoptosis could be inhibited by interruption of PTEN and AR interaction by adding AR-D peptide. Furthermore, using the PTEN siRNA and PTEN-null MEFs we found that AR protein levels and transcriptional activity were elevated. Taken together, these results indicate that PTEN is a negative regulator for controlling the AR activity and that interaction between AR and PTEN may play an important role for PTEN to suppress AR and induce apoptosis in prostate cancer cells.
Like other members of the steroid receptor superfamily, AR may move dynamically between the nucleus and the cytoplasm (40) . As androgen induces AR nuclear translocation and prolongs the half-life of AR (41), it is generally accepted that AR degradation might be prevented by binding androgen and translocating into the nucleus. Because PTEN suppresses AR nuclear translocation and promotes AR degradation, it is possible that these two events occur subsequently and are functionally linked. It is likely that PTEN may first bind to AR, leading to retention of this PTEN-AR complex in the cytoplasm, which may then make AR more vulnerable to enzymatic degradation.
Sequence analysis indicates that AR contains the nuclear localization signal (NLS) (aa 617 to 633) in the hinge region between DBD and LBD. It has been reported that mutations in the NLS may lead to the disruption of AR nuclear translocation (42) . It is plausible that PTEN binds to the hinge region of AR resulting in the interruption of the NLS nuclear translocation. Alternatively, PTEN could simply compete with other AR coregulators for binding to the same region, causing the inhibition of the nuclear translocation.
Recent reports suggest that PTEN may exert its biological activity by regulating stability of proteins. For example, PTEN can regulate the ubiquitin-dependent degradation of CDK inhibitor p27
Kip1 through the ubiquitin E3 ligase SCF Skp2 (38) . PTEN can also attenuate the hypoxia-mediated HIF-1␣ (hypoxia-inducible factor 1) stabilization (43) . Together with our finding showing that PTEN promotes AR degradation, these results support a role of PTEN in modulation of protein degradation. Proteins containing the PEST sequence A, 293T cells were transfected with PTEN siRNA or vector along with AR and green fluorescent protein (GFP) for 24 h, followed by ethanol or 10 nM DHT treatment for another 24 h, and harvested for Western blot analysis. GFP expression was used for transfection and loading control. B, 293T cells were transfected with various amounts of PTEN siRNA or vector along with AR and MMTV-luc for 24 h, followed by ethanol or 10 nM DHT treatment for another 24 h, and harvested for luciferase assay. C, WT and PTEN-null MEFs were transfected with AR and GFP in the presence or absence of PTEN for 36 h and harvested for Western blot analysis. GFP expression was used for transfection and loading control. D, WT and PTEN-null MEFs were transfected with plasmids as indicated for 24 h, followed by ethanol or 10 nM DHT treatment for another 24 h, and harvested for luciferase assay. *, P Ͻ 0.05; **, P Ͻ 0.001 vs. control (indicated as F), Student's two-tailed t test. are thought to be the target proteins for ubiquitination and degradation (44) . As AR contains the PEST sequence (aa 638 to 658) in the hinge region (45) , it is possible that PTEN accelerates AR degradation through the ubiquitin-proteosome pathway via the PEST sequence. However, this hypothesis is not supported by our result showing that PTEN-induced AR degradation is not affected by the treatment of the proteasome inhibitor MG132 (see supplemental Fig.  1A) , suggesting the unlikelihood that PTEN goes through the ubiquitin-proteasome pathway to promote AR degradation. As the caspase-3 inhibitor completely blocked the effect of PTEN on AR degradation (see supplemental Fig. 1A ), caspase-3 may mediate the PTEN-induced AR degradation. This hypothesis is further supported by our result (see supplemental Fig.  1B ) and the earlier report showing that caspase-3 could degrade AR in vitro (39) . It has been reported that PTEN-induced apoptosis can be rescued by caspase-3 inhibitor in LNCaP cells (46) , which also strengthens our hypothesis that PTEN signaling can be mediated through caspase-3 via direct cleavage of AR protein (39) . Although our study demonstrates that PTEN-mediated AR degradation is through caspase-3 activity (see supplemental Fig. 1 ), we found that the repression of AR activity by PTEN could not be rescued by a caspase-3 inhibitor or a general caspase inhibitor (see supplemental Fig. 1C ). These contrasting results imply that PTEN suppression of AR might go through multiple pathways, and caspase-3-mediated degradation could be one of these pathways. In addition, because it has been known that caspase-3 cleaves AR at the D151 residue, we further tested the effect of PTEN on AR-D151N mutant. We found that PTEN can still repress the transactivation of AR-D151N (see supplemental Fig. 1D ), indicating that PTEN suppressed AR not only via protein degradation. Because PTEN-dPTP (lacking AR interacting domain) failed to suppress AR transactivation (Fig. 6E) and AR-D (interaction inhibitor) can block the suppressive effect of PTEN on AR transactivation (Fig. 6 , A-C and F), it is possible that in addition to degradation of AR, direct association between AR and PTEN may also contribute to suppression of AR activity.
We reported recently that the PI3K/Akt pathway promoted AR ubiquitylation, leading to AR degradation by the 26 S proteasome (47) . These data clearly suggest that both PTEN and the PI3K/Akt pathway can promote AR degradation via distinct mechanisms. How can PTEN negatively regulate the PI3K/Akt pathway and at same time promote AR degradation? Because PI3K/Akt signaling promotes AR degradation, PTEN inhibition of this pathway would be expected to result in increased AR protein levels. It is possible that PTEN can go through both pathways by inhibition of PI3K/Akt-mediated AR degradation by the 26 S proteasome and caspase-3-mediated AR degradation. Yet the overall balance may favor the caspase-3-mediated AR degradation.
Because the interaction between PTEN and AR plays an important role in PTEN-mediated AR degradation (Fig. 5A) , it is possible that PTEN binding to AR may be required to expose the active site of the AR for caspase-3 recognition, thus leading to AR degradation. This hypothesis is supported by the demonstration that some apoptosis inducers, such as staurosporine and phorboester (phorbol myristate acetate), can induce caspase-3 activation (48, 49) , but fail to induce AR degradation (data not shown) (50) .
A mutant PTEN C124S, which does not have phosphatase activity, exhibits a significantly reduced ability to suppress AR activity in LNCaP and DU145 cells, indicating that PTEN phosphatase activity is important for PTEN-mediated AR suppression. Given that PTEN directly interacts with AR and that its phosphatase activity is important for its effect on AR activity, it is possible that PTEN may regulate AR activity via direct dephosphorylation of AR. However, we were unable to detect a significant change in AR phosphorylation upon addition of GST-PTEN in an in vitro dephosphorylation assay (data not shown). These data raise the possibility that PTEN may regulate AR activity, in part, via indirectly affecting the phosphorylation status of other proteins.
The loss of PTEN expression in prostate LNCaP cells leads to constitutive activation of Akt (15) . Akt is an important survival factor in a variety of cell types including LNCaP cells (15) . Several lines of evidence have indicated that PI3K/Akt is able to suppress cell apoptosis induced by growth factor deprivation (16, 51, 52) . Abrogation of PI3K/Akt activity by PI3K inhibitors causes LNCaP cell apoptosis (53, 54) . On the other hand, the androgen/AR signal is thought to play important roles in the prostate cancer cell growth and survival, and this signal can protect cells from apoptosis in response to treatment with PI3K inhibitors (54, 55) . Thus, the PI3K/Akt and the androgen/AR signaling pathways represent two major survival pathways in the LNCaP prostate cancer cells. As PTEN could repress the androgen/AR signal and PI3K/Akt pathway in LNCaP cells, we propose that inhibition of these two pathways by PTEN might contribute to PTEN-induced cell apoptosis in the LNCaP prostate cancer cells. This assertion was further supported by the observation that restoration of AR function or the PI3K/Akt pathway rescues cells from PTEN-induced apoptosis (Fig. 6F) .
Consistent with the reporter gene assay (Fig. 1E,  right panel) , in the high-passage number LNCaP cells we found that PTEN could down-regulate AR protein levels and this effect was reversed by Akt (Fig. 5E) . Furthermore, Akt did not down-regulate AR protein levels (Fig. 5E ), suggesting that Akt might not promote AR ubiquitylation and degradation in high-passage LNCaP cells. Based on our data we propose a model for PTEN action on AR signaling in prostate cancer LNCaP cells. PTEN regulates AR activity in lowpassage LNCaP cells via a PI3K/Akt-independent pathway and interacts directly with AR to suppress androgen-induced AR nuclear translocation. The interaction between AR and PTEN might expose the active site of the AR for the recognition of caspase-3. The PTEN activated caspase-3 then recognizes the AR and leads to AR degradation (Fig. 8) . Although overexpression of the active form of Akt can inhibit PTEN-induced caspase-3 activation, thus potentially blocking PTEN-mediated AR degradation, Akt itself can induce AR degradation. This may explain why restoration of Akt activity does not reverse PTENmediated AR suppression and AR degradation in the early-passage number LNCaP cells. In contrast, PTEN promotes AR degradation and suppress AR activity in high-passage number LNCaP cells via a PI3K/Aktdependent pathway (Fig. 8) . In such cells, Akt does not down-regulate AR protein levels (perhaps not inducing AR degradation), and it may account for the reason why PTEN-induced suppression of AR activity and AR degradation are inhibited by restoration of Akt activity. Several important questions have been raised throughout this study. First, what is the factor(s) that determines the differential effects of the PI3K/Akt pathway on AR activity in different passage numbers of LNCaP cells? What factor(s) triggers the distinct mechanisms used by PTEN to regulate AR activity in various passage numbers of LNCaP cells? What factor(s) can be dephosphorylated by PTEN and also contribute to PTEN-mediated AR suppression? Future studies should focus on these issues, and systematic analysis is required to solve these puzzles.
MATERIALS AND METHODS
Constructs and Reagents
pCDNA3-cAkt and pCDNA3-dAkt were from Dr. R. Freeman. LY294002, DEVD-CHO, and z-VAD-FMK were from Calbiochem (La Jolla, CA). 5␣-Dihydrotestosterone (DHT) and Dox were from Sigma Chemical Co. (St. Louis, MO). The anti-AR polyclonal antibody, NH27, was produced as previously described (8, 56) . Recombinant active caspase-3 was purchased from Pharmingen (San Diego, CA). PTEN monoclonal antibody was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). FITC-conjugated secondary antimouse antibody and Texas Red-conjugated secondary antirabbit antibody were from ICN Biochemicals, Inc. (Aurora, OH). TNT in vitro protein expression kit was from Promega. pCDNA3-PTEN and pCDNA3-PTEN C124S were provided by Dr. C. L. Sawyers. pSG5-HA-PTEN was from Dr. W. Sellers. PTEN-no. 1 (encoding PTEN aa 1-107) and AR-D (encoding AR aa 486-651) were constructed into pCMV-FLAG vector. To construct GST-PTEN fragment proteins, the PTEN fragments (nos. 1, 2, and 3) were released from pGEX-KG-PTEN (from Dr. F. Furnari) and subcloned into pGEX-KG, pGEX-2t, and pGEX-3x (Amersham Pharmacia Biotech, Arlington Heights, IL), respectively. To construct GST-PTEN-PTP, the PTP fragment was obtained by PCR and inserted into pGEX-3x. pCDNA3-FLAG-PTEN and pCDNA3-FLAG-PTEN-dPTP (lacking PTEN aa 110-200) were generated by PCR, and the cDNAs were inserted into pCDNA3 vector (Invitrogen).
Cell Culture and Transfections
The DU145, PC-3, 293T, COS-1, and the wild-type (WT) and PTEN-null MEFs (kindly provided by Dr. H. Wu) were maintained in DMEM containing penicillin (25 U/ml), streptomycin In low-passage number LNCaP cells, the PI3K/Akt pathway suppresses AR activity and induces AR ubiquitylation and degradation by 26S proteasome (47) . PTEN tumor suppressor also suppresses AR activity at this early-passage number of LNCaP cells via a PI3K/Akt-independent pathway. PTEN directly interacts with AR and induces caspase-3 activation. The interaction between AR and PTEN may lead AR to expose the active site for caspase-3 recognition, resulting in AR degradation. Furthermore, the interaction between AR and PTEN results in suppression of AR nuclear translocation. However, the PI3K/Akt enhances AR activity in high-passage number LNCaP cells via an unknown mechanism. PTEN, on the other hand, suppresses AR activity via a PI3K/Akt-dependent pathway.
(25 g/ml), and 10% fetal calf serum (FCS). The LNCaP, U87MG, and CWR22R (a gift from Dr. C. Kao) cells were maintained in RPMI-1640 with 10% FCS. Transfections were performed using the calcium phosphate precipitation method in PC-3 and DU145 cells, as previously described (57) or SuperFect in LNCaP, COS-1, and U87MG cells according to standard procedures (QIAGEN, Chatsworth, CA).
Apoptosis Assay
For the apoptosis assay, the cells were transfected with plasmids for 24 h and grown in 0.1% charcoal dextranstripped serum (CDS) media. The apoptosis was determined 2 d after transfection using the TUNEL assay according to the standard procedures (Oncogene Science, Inc., Manhasset, NY). At least 200 cells were scored for each sample, and data are means Ϯ SD from three independent experiments.
Luciferase Reporter Assays
The cells were transfected with plasmids in 10% CDS media for 16 h and then treated with ethanol or 10 nM DHT for 16 h. The cells were lysed and the luciferase activity was detected by the dual luciferase assay according to standard procedures (Promega). The results were normalized by pRL-SV40 activity, and the data are represented as means Ϯ SD from at least three independent experiments.
Glutathionine-S-transferase (GST) Pull-Down Assay
The GST pull-down assay described previously (58) was performed with some modifications. GST-fusion proteins were purified as described by the manufacturer (Amersham Pharmacia Biotech). The purified GST-proteins were resuspended with 100 l of interaction buffer [20 mM Tris-HCl (pH 8.0), 60 mM NaCl, 1 mM EDTA, 6 mM MgCl 2 , 1 mM dithiothreitol, 8% glycerol, 0.05% (vol/vol) Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitors] and mixed with 5 l of 35 S-labeled TNT proteins in the presence or absence of 1 M ligands on a rotating disk at 4 C for 2 h. After extensive washes with NENT buffer (20 nM Tris-HCl/pH 8.0, 100 mM NaCl, 6 mM MgCl 2 , 1 mM EDTA, 0.5% (vol/vol) Nonidet P-40, 1 mM dithiothreitol, 8% glycerol, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitors) bead-bound proteins were separated on an 8% sodium dodecyl sulfate-polyacrylamide gel and visualized by autoradiography.
Immunoprecipitation and Western Blot Analysis
The immunoprecipitation and Western blotting were performed as previously described (59) . The cell extracts (1 mg) were immunoprecipitated with the indicated antibody. The immunocomplexes were subjected to 8% SDS-PAGE and immunoblotted with the indicated antibodies.
Immunofluorescence and Microscopy
The COS-1 cells were plated on 12-mm coverslips, incubated overnight, and transfected with pSG5-AR in combination with pCDNA3, pCDNA3 PTEN, or pCDNA3 PTEN C124S in 10% CDS media for 16 h, followed by the treatment with ethanol or 10 nM DHT for another 16 h. The cells were fixed with 4% paraformaldehyde/PBS for 20 min on ice and permeabilized with 100% methanol for 15 min on ice. The following experiments were performed at room temperature. The coverslips were rinsed with PBS twice and incubated in 5% BSA for 30 min. The primary antibodies against AR and PTEN were added for 1 h and then washed with PBS four times. The secondary antibodies were added for 1 h, and the coverslips were washed four times with PBS, followed by application of the counting medium containing 4Ј,6-diaminodino-2-phenylindole. Coverslips were examined by confocal microscope. A FITC-conjugating antimouse antibody and a Texas Red antirabbit antibody were used as secondary antibodies.
LNCaP Stable Transfectants
For the Dox-inducible system, PTEN or PTEN C124S were released from pGEX-KG-PTEN or pGEX-KG-PTEN C124S using EcoRI digestion and inserted into pBIG2i vector. The LNCaP cells were transfected with pBIG2i vector, pPIB2i PTEN, or pBIG2i PTEN C124S for 24 h. The cells were selected with 100 g/ml hygromycin B. Individual colonies were picked up and grown until 70% confluent, followed by 4 g/ml Dox treatment for 48 h. The positive clones were confirmed by Western blot analysis.
Pulse-Chase Experiments
Pulse-chase experiments were performed as described (60) with some modifications. Briefly, COS-1 cells were transfected with pSG5-AR in combination with pCDNA3 or pCDNA3 PTEN in 10% CDS media for 36 h. Cells were grown under serum starvation conditions for 2 h in methionine/ cysteine-deficient medium, and then the cells were pulsed for 45 min with 200 Ci/ml [ 35 S]methionine/cysteine (NEN Life Science Products, Boston, MA). Cells were washed with DMEM twice and incubated with DMEM containing 0.2% CDS along with 10 nM DHT. The cells were lysed by RIPA buffer in the presence of protease inhibitors, followed by immunoprecipitation using AR antibody. The immunocomplexes were subjected to 8% SDS-PAGE and visualized by autoradiography.
Construction of PTEN siRNA
A small-interfering RNA (siRNA) was expressed in mammalian cells by transfection of a DNA-based vector BS/U6 (61) containing a homologous sequence (CCCACCACAGCTA-GAACTTATC), a 6-bp spacer (CTCGAG), an inverted homologous sequence (GATAAGTTCTAGCTGTGGTGGG), and 5 "T"s, at the transcription initiation site of the U6 promoter.
